PURCHASE, N.Y., March 10, 2025 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), announced that President and CEO Lisa Ricciardi will present live at the Life Sciences Virtual Investor Conference on March 13, 2025 at 9:30 a.m. ET. In her presentation, Ms. Ricciardi will review plans for 2025 to support the advancement of zervimesine (CT1812) in Alzheimer’s disease and dementia with Lewy bodies following the Company’s positive Phase 2 data readouts.
This will be a live, interactive, online event. Members of the management team will be available to answer questions in real time. If attendees are not able to join the event live on the day of the conference, an archived webcast will be made available on Cognition’s Investor Relations webpage. It is recommended that investors interested in attending the live event pre-register to expedite their participation and receive event updates. To register, please visit www.virtualinvestorconferences.com.
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc., is a clinical-stage biopharmaceutical company discovering and developing innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We currently are investigating our lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease, including the ongoing START study (NCT05531656) in early Alzheimer’s disease. We believe zervimesine and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases that are functionally distinct from other approaches for the treatment of degenerative diseases. More about Cognition Therapeutics and our pipeline can be found at https://cogrx.com.
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is …
